{
 "id": "thyroid-cancer",
 "name": "Thyroid cancer",
 "aliases": [],
 "acronyms": [],
 "bodySystem": "cancer",
 "parent": null,
 "children": [
  "medullary-thyroid-cancer",
  "metastatic-differentiated-thyroid-cancer"
 ],
 "edition": "2026-11",
 "merkleRoot": "006ab9a329709cbe7f56a0e1a7c4a02f897655cdfecf9ca34d199690095adcb6",
 "builtFrom": "program.status and program.eligibility facts, grouped by the condition registry",
 "counts": {
  "open": 0,
  "limited": 0,
  "waitlist": 0,
  "closed": 1
 },
 "funds": [
  {
   "fund": "Thyroid cancer",
   "organization": "TotalAssist (Patient Advocate Foundation copay funds)",
   "status": "closed",
   "dateOnPage": null,
   "awardLevelUsd": 8200,
   "insuranceTypes": [
    "Medicaid",
    "Medicare",
    "TRICARE"
   ],
   "pageSays": "The page lists the fund as Closed.",
   "readOn": "2026-11-08",
   "source": "https://totalassist.org/funds/"
  }
 ],
 "drugsWhoseLabelNamesThisCondition": [
  {
   "ingredient": "Dabrafenib Mesylate",
   "pages": [
    {
     "brand": "Tafinlar",
     "url": "https://omnirx.org/medicines/tafinlar"
    }
   ],
   "labelSentence": "... the treatment of patients with locally advanced or metastatic anaplastic thyroid cancer (ATC) with BRAF V600E mutation, as detected by an FDA-approved test, and with no satisfactory locoregional treatment options.",
   "labelContext": "indication",
   "labelSource": "https://api.fda.gov/drug/label.json?search=set_id:%22fee1e6b1-e1a5-4254-9f2e-a70e0f8dbdea%22&limit=1",
   "labelRead": "2026-11-10",
   "manufacturerPrograms": [
    {
     "name": "Novartis Patient Assistance Foundation (NPAF)",
     "url": "https://pap.novartis.com/medications-list/",
     "programPageIsExternal": true,
     "inCurrentList": true,
     "note": null,
     "listKind": "NPAF medications list",
     "status": null,
     "statusRead": null
    }
   ],
   "medicareNegotiatedPrice": null
  },
  {
   "ingredient": "Levothyroxine Sodium",
   "pages": [
    {
     "brand": "Synthroid",
     "url": "https://omnirx.org/medicines/synthroid"
    }
   ],
   "labelSentence": "... oxine sodium tablets are indicated in adult and pediatric patients, including neonates, as an adjunct to surgery and radioiodine therapy in the management of thyrotropin-dependent well-differentiated thyroid cancer.",
   "labelContext": "indication",
   "labelSource": "https://api.fda.gov/drug/label.json?search=set_id:%22008de8fd-150f-4022-8ccb-c8bfa94875c7%22&limit=1",
   "labelRead": "2026-11-10",
   "manufacturerPrograms": [
    {
     "name": "myAbbVie Assist",
     "url": "https://omnirx.org/assistance/abbvie-myabbvie-assist",
     "programPageIsExternal": false,
     "inCurrentList": true,
     "note": null,
     "listKind": "Available medicines (myAbbVie Assist)",
     "status": null,
     "statusRead": null
    }
   ],
   "medicareNegotiatedPrice": null
  },
  {
   "ingredient": "Trametinib Dimethyl Sulfoxide",
   "pages": [
    {
     "brand": "Mekinist",
     "url": "https://omnirx.org/medicines/mekinist"
    }
   ],
   "labelSentence": "... the treatment of patients with locally advanced or metastatic anaplastic thyroid cancer (ATC) with BRAF V600E mutation, as detected by an FDA-approved test, and with no satisfactory locoregional treatment options.",
   "labelContext": "indication",
   "labelSource": "https://api.fda.gov/drug/label.json?search=set_id:%220002ad27-779d-42ab-83b5-bc65453412a1%22&limit=1",
   "labelRead": "2026-11-10",
   "manufacturerPrograms": [
    {
     "name": "Novartis Patient Assistance Foundation (NPAF)",
     "url": "https://pap.novartis.com/medications-list/",
     "programPageIsExternal": true,
     "inCurrentList": true,
     "note": null,
     "listKind": "NPAF medications list",
     "status": null,
     "statusRead": null
    }
   ],
   "medicareNegotiatedPrice": null
  },
  {
   "ingredient": "LENVATINIB",
   "pages": [
    {
     "brand": "Lenvima",
     "url": "https://omnirx.org/negotiated-drugs/lenvima"
    }
   ],
   "labelSentence": "Differentiated Thyroid Cancer (DTC) For the treatment of adult patients with locally recurrent or metastatic, progressive, radioactive iodine-refractory differentiated thyroid cancer (DTC).",
   "labelContext": "indication",
   "labelSource": "https://api.fda.gov/drug/label.json?search=set_id:%22f4bedd21-efde-44c6-9d9c-b48b78d7ed1e%22&limit=1",
   "labelRead": "2026-11-10",
   "manufacturerPrograms": [],
   "medicareNegotiatedPrice": {
    "usd30DaySupply": null,
    "effective": "2028-01-01",
    "source": "https://www.cms.gov/initiatives/medicare-prescription-drug-affordability/overview/medicare-drug-price-negotiation-program/selected-drugs-negotiated-prices"
   }
  },
  {
   "ingredient": "Cabozantinib S-Malate",
   "pages": [
    {
     "brand": "Cabometyx",
     "url": "https://omnirx.org/medicines/cabometyx"
    }
   ],
   "labelSentence": "COMETRIQ is indicated for the treatment of patients with progressive, metastatic medullary thyroid cancer (MTC).",
   "labelContext": "indication",
   "labelSource": "https://api.fda.gov/drug/label.json?search=set_id:%221a0c3bea-c87b-4d25-bb44-5f0174da6b34%22&limit=1",
   "labelRead": "2026-11-10",
   "manufacturerPrograms": [],
   "medicareNegotiatedPrice": null
  }
 ],
 "fundsForRelatedCosts": [
  {
   "fund": "American Cancer Society Cancer Care Continuity Fund",
   "organization": "Patient Advocate Foundation",
   "status": "closed",
   "readOn": "2026-11-08",
   "source": "https://www.patientadvocate.org/connect-with-services/financial-aid-funds/"
  },
  {
   "need": "testing",
   "fund": "Cancer genetic and genomic testing",
   "organization": "TotalAssist (Patient Advocate Foundation copay funds)",
   "status": "open",
   "readOn": "2026-11-08",
   "source": "https://totalassist.org/funds/"
  },
  {
   "need": "home care",
   "fund": "Cancer Home Care Services",
   "organization": "HealthWell Foundation",
   "status": "open",
   "readOn": "2026-11-08",
   "source": "https://www.healthwellfoundation.org/disease-funds/"
  },
  {
   "need": "behavioral health",
   "fund": "Cancer-Related Behavioral Health",
   "organization": "HealthWell Foundation",
   "status": "closed",
   "readOn": "2026-11-08",
   "source": "https://www.healthwellfoundation.org/disease-funds/"
  },
  {
   "need": "pain management",
   "fund": "Cancer-Related Pain Management",
   "organization": "CancerCare",
   "status": "closed",
   "readOn": "2026-11-08",
   "source": "https://www.cancercare.org/copayfoundation"
  },
  {
   "need": "caregiver support",
   "fund": "CancerCare CAR-T Caregiver Assistance Fund",
   "organization": "CancerCare",
   "status": "closed",
   "readOn": "2026-11-08",
   "source": "https://www.cancercare.org/copayfoundation"
  },
  {
   "need": "caregiver support",
   "fund": "CancerCare Caregiver Financial Assistance Fund(s)",
   "organization": "CancerCare",
   "status": "closed",
   "readOn": "2026-11-08",
   "source": "https://www.cancercare.org/copayfoundation"
  },
  {
   "need": "clinical trial costs",
   "fund": "CancerCare Clinical Trial Financial Assistance Fund",
   "organization": "CancerCare",
   "status": "closed",
   "readOn": "2026-11-08",
   "source": "https://www.cancercare.org/copayfoundation"
  },
  {
   "need": "transportation",
   "fund": "CancerCare Gets You There - Transportation Assistance Fund(s)",
   "organization": "CancerCare",
   "status": "closed",
   "readOn": "2026-11-08",
   "source": "https://www.cancercare.org/copayfoundation"
  },
  {
   "need": "behavioral health",
   "fund": "Oncology Caregiver Behavioral Health Fund (Accepting phone applications only)",
   "organization": "HealthWell Foundation",
   "status": "open",
   "readOn": "2026-11-08",
   "source": "https://www.healthwellfoundation.org/disease-funds/"
  }
 ],
 "note": "Each status is what the fund page said on readOn. It is not an eligibility determination. We hold only the organizations we read; no fund here does not mean no fund exists.",
 "licence": "CC BY 4.0 for the OmniRx compilation"
}